Alzheimer's Disease Genetics Study

Alzheimer Disease Clinical Trial

— NCRAD  

Official title:

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00064870
• Other study ID #: IA0042
• Secondary ID: U24AG021886NIH g
• Status: Recruiting
• Start date: June 2002
• Est. completion date: July 2026

Study information

• Verified date: March 2024
• Source: Indiana University
• Contact: Study Coordinator
• Phone: 1-800-526-2839
• Email: alzstudy[@]iu.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed with AD or dementia.

Description:

The purpose of the Alzheimer's Disease Genetics Study is to help identify the genes that may be responsible for causing Alzheimer's Disease (AD) by collecting genetic material from families with multiple members diagnosed with AD. Qualifying families will have two living blood-related individuals who have been diagnosed with or are showing symptoms of AD or dementia. Local study sites are located all over the United States, and arrangements may be made for eligible families who do not live near a participating site. The biological samples and data from these families will be made available to qualified researchers, who must sign a Materials Transfer Agreement (MTA) in order to protect the privacy rights of study participants before receiving samples and data.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10000
• Est. completion date: July 2026
• Est. primary completion date: July 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Two living family members diagnosed with AD or other dementia with any age of onset

• Biological samples available

• Fresh blood, or

• Immortalized lymphoblastic cell lines, or

• 3-5 grams of frozen cerebral cortex; fixed samples are not accepted

Please note: this study does not include genetic counseling; because no personal identifying information such as name or date of birth is attached to samples, results of individual tests are not available to participants or family members.

Exclusion Criteria:

• Does not meet inclusion criteria

• Member of a family that was included in the National Institute of Mental Health AD Genetics Sib Pair collection

Related Conditions & MeSH terms

• Alzheimer Disease
• Dementia
• Late Onset Alzheimer Disease

Locations

Country	Name	City	State
United States	Participants are being recruited from all over the United States	Multiple Locations	Indiana

Sponsors (2)

Lead Sponsor	Collaborator
Indiana University	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Distribute biological specimens to qualified investigators for use in their research studies.	Investigators will analyze the samples and publish de-identified results. These publications will help to further the knowledge in the field of dementia and potentially lead to new therapies and targets for therapies.	Contact investigators annually for an update on progress and publication status.

External Links

•   NCRAD: the National Centralized Repository for Alzheimer's Disease and Related Dementias